Collegium Pharmaceutical (COLL) risk factors

Item 1A of every Collegium Pharmaceutical, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open COLL in Gloom →

Collegium Pharmaceutical's chart, financials and news, free in your browser.Open COLL in Gloom →

FY2025 10-K risk factors
38 risks3 new3 dropped11 reworded
New risks emphasize third-party manufacturing compliance, acquisition integration, and AI-related confidentiality and cybersecurity exposure.
Filed Feb 26, 2026
FY2024 10-K risk factors
38 risks
Dependence on commercializing key products like Jornay, Belbuca, Xtampza, Nucynta, and Symproic drives company risks.
Filed Feb 27, 2025